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Abstract Objective Cost-related medication non-adher-
ence is associated with increased health-care resource
utilization and poor patient outcomes. Physicians-in-train-
ing generally receive little education regarding costs of
prescribed therapy and may rely on hospital pharmacists
for this information. However, little is documented
regarding either of these health care providers’ familiarity
with out-of pocket medication expenses borne by patients
in the community. The purpose of this study was to eval-
uate and compare resident physician and hospital
pharmacist familiarity with what patients pay for medica-
tions prescribed once discharged. Setting A major tertiary
patient care and medical teaching centre in Canada.
Method Internal medicine residents and hospital pharma-
cists within a specific health care organization were invited
to participate in an online survey. Eight patient case sce-
narios and associated discharge therapeutic regimens were
outlined and respondents asked to identify the costs
patients would incur when having the prescription filled
once discharged. Main Outcome Measure Total number
and proportion of estimates above and below actual cost
were calculated and compared between the groups using v2
tests. Responses ±10% of the true cost were considered
correct. Mean absolute values and standard deviation
estimated costs, as well as cost increments above and
below 10%, were calculated to assess the magnitude of the
discrepancy between the respondent estimates and the
actual total cost. Results Forty-four percent of physician
residents and 26% of hospital pharmacists accessed the
survey. Overall 39% and 47% of medication costs were
under-estimated, 32% and 33% were overestimated, and
29% and 21% were correctly estimated by residents and
pharmacists, respectively (P = NS). Incorrect estimates
were evident across all therapeutic classes and medical
indications presented in the survey. The greatest absolute
cost discrepancy for both groups was under-estimation of
linezolid ($800 and $400) and over-estimation of clopi-
dogrel ($80) and bisoprolol therapy ($22) by residents and
pharmacists, respectively. Conclusion Resident physicians
and hospital pharmacists are unfamiliar with what patients
must pay for drug therapy once discharged.
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Impact statement of research findings on practice:
• Drug costs are a barrier to medication adherence for
many patients and can be a source of failed therapeutic
outcomes.
• Residents and physicians are often unfamiliar with the
cost of their prescribed therapy.
• Hospital pharmacists and resident physicians similarly
lack an appreciation of medication costs.
Introduction
Prescription drug spending continues to outpace every
other segment in health care as medications become more
expensive, prescribing preferences shift to novel and more
costly therapies and medication use rises with the aging
population [1].
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A common measure to control drug expenditures is
implementation of cost-sharing strategies such as user fees
that require consumers to assume a portion of prescription
cost. As health care costs escalate, employers are increas-
ingly shifting the proportion of drug costs they bear to the
individual. Despite private or public drug benefit coverage,
patients may be subject to higher co-payments, deductibles,
as well as reimbursement and formulary restrictions [2, 3].
Drug therapy poses a financial burden for many patients
and those who face high out-of-pocket medication expen-
ses are less likely to purchase prescribed therapy [4–6].
Similarly, these patients may resort to administration
minimization strategies such as inappropriate alternate day
dosing or as needed use to decrease medication expendi-
tures [7, 8]. Inability of individuals to pay for medication
ultimately increases the cost to health care systems [9, 10].
Consequences of cost-related non-adherence include
increased use of emergency department and health care
services as well as reduction in overall health status and are
virtually always attributed to patients foregoing essential
drug therapy [2, 11–15].
Health professionals developing discharge medication
regimens from in-patient care settings may not always be
aware of patients’ specific drug therapy coverage or
appreciate prescription costs in the community. It has been
previously found that physicians do not routinely ask if
patients have possible medication payment difficulties and
are often uninformed about the costs associated with their
prescribed therapy [2, 16–20]. Physicians-in-training (stu-
dents, interns, residents) generally receive limited formal
education regarding costs of medical care, including pre-
scriptions [21]. In a teaching hospital, resident physicians
may rely on pharmacist members of the multi-disciplinary
team for this information. However, there is surprisingly
little information regarding hospital pharmacists’ knowl-
edge of patient medication costs in the community.
Pharmacists unacquainted with specific discrepancies
between their hospital formulary systems and outpatient
medication reimbursement structures forfeit the opportu-
nity to recommend more affordable therapeutic alternatives
to resident physicians prior to patient discharge. Thera-
peutic regimens initiated in hospital may then be
interrupted due to financial hardship and patient outcomes
compromised [22].
Aim of the study
The purpose of this study was to evaluate and compare
medical resident physician and hospital pharmacist famil-
iarity with how much patients pay for medications
prescribed once discharged.
Method
In May 2007, internal medicine residents training and
hospital pharmacists employed within four hospitals within
a principle health authority in British Columbia, Canada
were contacted by email and invited to participate in an
online survey.
Subsequent survey questions presented eight brief
patient case scenarios describing six typical reasons for
hospital admission to the internal medicine service at the
major tertiary care centre within this health authority
according to hospital census data. Specific discharge ther-
apeutic regimens were outlined with each patient case
scenario and the resident physicians and pharmacists asked
to estimate the associated discharge cost. These regimens
were selected in accordance with best medical practice
according to established clinical guidelines or likely
microbiological data (e.g. the infectious diseases-related
cases). Respondents were instructed to consider both direct
drug costs and pharmacist professional fee when approxi-
mating the total cost a patient would pay at a local
community pharmacy. It was identified in each case that
patients had no third party coverage and would therefore
incur the total cost of therapy themselves and that generic
medication would be dispensed when available for alter-
natives illustrated in the scenarios.
The survey took approximately 20 min to complete.
Two subsequent reminder messages were sent at 3-week
intervals to encourage resident physicians and pharmacists
to complete the online survey.
Actual costs of the discharge therapeutic regimens
described in the patient case scenarios were obtained from
three Greater Vancouver community pharmacies repre-
senting three different drug store chains. The mean value of
each reported medication cost was used to compare with
those costs estimated by survey respondents. All prices are
reported in Canadian dollars.
Each drug regimen cost estimate was compared to the
true cost and the absolute error (true cost minus estimate)
calculated. The total number and proportion of resident
physician and pharmacist estimates that were either above
or below the actual cost were calculated. Responses within
10% of the actual total cost were considered correct. Mean
absolute values and standard deviation of estimated costs,
as well as cost increments above and below 10%, were
calculated to permit assessment of the magnitude of the
discrepancy between the respondent estimates and the
actual total cost. Correct price interval estimates were
coded with a value of zero and the range of incorrect
estimates were coded as the absolute value of the number
of 10% intervals above or below the correct interval. Mean
scores closer to zero therefore indicate greater familiarity
with discharge regimen price. Incomplete surveys were
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included in the analysis and proportional data were
expressed in terms of the number of respondents who
answered a particular question.
All data analysis was conducted using SPSS for Win-
dows standard version release 16.0 Excel (SPSS
Inc.,Chicago, Illinois). Categorical data are presented as
percentages of frequency or occurrence. Continuous data
are presented as means with standard deviations (SD). The
two groups’ responses were compared using Chi-square
tests. All statistical tests were 2-tailed and based on a
significance level of a B 0.05.
Results
The email invitation was distributed to the 96 physicians in
the internal medicine residency training program and 146
hospital pharmacists, of whom 25 (26%) and 64 (43.8%),
respectively accessed the online survey to participate.
For the total 29 alternative discharge regimens described
in the six patient case scenarios, 39% and 46% of medi-
cation costs were under-estimated, 32% and 33% were
over-estimated, and 29% and 21% were correctly estimated
by resident physicians and pharmacists, respectively
(Fig. 1).
Nearly half of all alternative discharge antibiotic therapy
costs were under-estimated by both groups, but more so by
pharmacists (36.0% and 44.4%, P = 0.047). Resident
physician and pharmacist overall estimates of discharge
medication costs for treatment of community-acquired
pneumonia or skin and soft tissue infections described in
the patient case scenarios were similarly incorrect. Spe-
cifically, most resident physician respondents under-
estimated cefuroxime and clarithromycin combination
therapy and over-estimated moxifloxacin discharge regi-
mens prescribed for pneumonia. Conversely, pharmacists
were more likely to under-estimate the price of cefuroxime
and over-estimate the price of azithromycin. Linezolid
Fig. 1 Resident physician and hospital pharmacists estimates of
discharge medication costs (Medication described on the y-axis
represent therapeutic alternatives offered in the survey patient case
scenarios. Pharmacists’ cost estimates of medication regimens were
considered correct if they fell within ±10% of the actual cost. Actual
medication regimen costs (±10%) were coded as zero. Therefore,
mean scores closer to zero indicate greater familiarity with the cost of
medication regimens. The range of cost estimates greater or less than
10% of the actual cost are also depicted. Each unit on the x-axis
represents one incorrect cost interval (±10% of actual cost). Resident
physician responses are illustrated in red.)
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therapy was most commonly under-estimated by both
groups, but to a greater extent by resident physicians, while
clindamycin and amoxicillin over-estimated by resident
physician and pharmacists, respectively, when treatment of
skin and soft tissue infection was considered.
Estimates of discharge proton pump inhibitor costs for
peptic ulcer disease were similarly under- (35.2% vs.
40.2%, NS) and over-estimated (51.1% vs. 41.1%, NS) by
resident physician and pharmacist respondents.
The discharge cost of carvedilol was most frequently
under-estimated and that of bisoprolol over-estimated
when beta blocker heart failure therapy scenarios were
assessed. Likewise, all respondents were unable to accu-
rately determine the cost of clopidogrel antiplatelet
therapy, although it was were more likely to be over-esti-
mated by resident physicians (52.4% vs. 8.3%, P = 0.001)
and under-estimated by pharmacists (10.1% vs. 69.4%,
P = 0.001).
Respondents largely under-estimated community phar-
macy expenses for diabetes treatment, including various
insulin formulations (57.1% vs. 54.4%, P = NS) and
thiazolidinediones (57.5% vs. 54.2%, P = NS).
Assessment of chronic obstructive pulmonary disease
(COPD) therapy was also incorrect as many respondents
under-estimated the price of salbutamol and ipratropium
metered dose inhalers (MDI) (95.4% vs. 91.3%, P = NS),
but over-estimated the cost of the combination product
(Combivent) (68.2% vs. 65.2%, P = NS).
When considering mean absolute costs, the greatest
under-estimation among both groups was of linezolid
therapy by an average of $800 for resident physicians and
nearly $400 for pharmacists. Resident physicians over-
estimated clopidogrel by $80 and pharmacist over-estima-
tion of bisoprolol therapy was by approximately $20
(Table 1). However, errors as a proportion of actual cost
(±10%) were most often found among insulin and car-
diovascular therapies: NPH (-6.8 and -4.3) and insulin
70/30 (13.9) and bisoprolol (25.7) by pharmacists and
resident physicians, respectively (Fig. 1).
Discussion
Both internal medicine resident physicians and hospital
pharmacists demonstrated poor knowledge of discharge
medication costs. Incorrect estimates were evident across
the spectrum of therapeutic classes and associated medical
indications presented in the survey. The expense borne by
patients at discharge was underestimated for half of the
proposed therapeutic regimens ranging from a few to
hundreds of dollars.
Patients are frequently discharged with new drug ther-
apies and more complex and costly regimens following
hospital stays [23, 24]. The economic factors of poly-
pharmacy, coupled with competing demands for household
resources may prevent patients from completing or sus-
taining intended therapy [25]. Cost-related decreases in
prescription medication use invariably impacts those most
vulnerable to poor outcome: the poor; the elderly; and the
chronically ill [2].
Our results reflect physician shortcomings in anticipat-
ing patient medication costs that are well established, but
less well-documented for physicians-in-training [16–21].
Existing data suggests they also have poor cost awareness,
undoubtedly linked to inexperience, as well as insufficient
information within medical education curricula [21].
Family practice residents previously surveyed in British
Columbia paradoxically overestimated the costs of inex-
pensive drugs and underestimated the costs of expensive
drugs [26]. In fact, some expressed frustration about their
ignorance and refused to participate because of it. How-
ever, when critical care staff were surveyed in another
study, professional experience (staff versus resident) had
no impact on discouraging cost estimate performance [27].
Physicians-in-training invariably receive informal teaching
from multidisciplinary team members during their practice
rotations, so it is particularly unfortunate and surprising for
hospital pharmacists to demonstrate inadequate knowledge
of drug prices. In one physician survey, over 50% believed
that pharmacists have a greater responsibility for managing
patients’ out-of-pocket costs than doctors [19]. Clearly,
physicians rely on pharmacists to inform patients of drug
therapy costs and intervene if possible when financial
obstacles are identified. Hospital pharmacists are respon-
sible for guiding all health staff involved in discharge
planning to ensure optimal medication outcomes for
patients, but this support is especially important in teaching
hospitals where novice prescribers are faced with other
patient care demands and stresses [28].
Hospital pharmacists should make an overt inquiry
regarding prescription drug coverage a routine part of
patient interactions. It has been previously demonstrated
that individuals are not necessarily forthcoming with
inabilities to support the costs of medication but expressed a
preference to discuss strategies to manage these expenses
with their health care provider [29, 30]. However, patients
may not be able to anticipate difficulties obtaining dis-
charge therapy if they are not advised of the potential cost to
fill prescriptions in the community. For this reason, both
resident physicians and hospital pharmacists need to
familiarize themselves and keep abreast with the costs of
the most common discharge therapies in their clinical
practice and any restrictive or supportive governmental
policies concerning specific patient or medication coverage.
It is not with the greatest ease that community physi-
cians or pharmacists can coordinate medication coverage
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or therapeutic substitution. Hospital pharmacists are in a
unique position to make timely interventions in the
selection of the most appropriate and affordable thera-
peutic regimen prior to patient discharge. Gaps in
seamless care is a disservice and inconvenience to both
patients and community pharmacist colleagues whose
ability to advocate for less expensive therapies is often
restricted by resources and information. Indeed, while
physicians feel pharmacists shoulder greater responsibility
for mediating prescription costs for patients, over half
responding to one survey felt that phone calls from
pharmacists were ‘‘bothersome’’ [19].
Table 1 Hospital pharmacists’ estimates of discharge medication costs
Discharge drug regimena Actual costb Resident physician
mean discrepancy (SD)c
Hospital pharmacist
mean discrepancy (SD)c
Community-acquired pneumonia
Moxifloxacin 400 mg po daily $51.98 $32.73 ($68.89) $-3.93 ($16.38)
Cefuroxime 500 mg po BID $39.99 $-3.23 ($28.24) $-11.79 ($11.69)
Cefuroxime ? clarithromycin 500 mg po BID $95.90 $-31.73 ($40.17) $-25.55 ($27.58)
Azithromycin 250 mg po daily (5 days) $27.94 $9.32 ($26.85) $12.13 ($15.12)
Doxycyline 100 mg po daily $19.10 $4.77 ($25.83) $-1.17 ($6.90)
Skin and soft tissue infection
Amoxicillin/clavulanate 875 mg po BID $29.28 $4.77 ($25.83) $12.82 ($17.24)
Cephalexin 500 mg po QID $19.21 $12.55 ($30.25) $2.25 ($13.46)
Clindamycin 450 mg po QID $39.39 $18.18 ($31.36) $-5.89 ($14.09)
Linezolid 600 mg po BID $1,088.08 -$782.50 ($326.98) $-384.18 ($757.01)
Penicillin VK 500 mg po QID $11.99 $37.45 ($103.74) $1.00 ($4.74)
Peptic ulcer disease
Rapebrazole 20 mg po daily 9 30 days $70.31 $-7.68 ($45.67) -$11.60 ($31.10)
Rabeprazole 20 mg po bid 9 30 days $95.33 $20.05 ($75.58) $18.60 ($64.19)
Esomeprazole 20 mg po daily 9 30 days $78.61 $29.86 ($109.80) $3.96 ($42.91)
Omeprazole 20 mg po daily 9 30 days $49.30 $35.68 ($95.63) $26.08 ($45.90)
Heart failure—beta blocker
Metoprolol 50 mg po BID $21.05 $24.50 ($36.18) $ 9.96 ($22.14)
Bisoprolol 10 mg po daily $21.92 $52.09 ($54.59) $ 22.42 ($20.48)
Carvedilol 50 mg po BID $109.55 -$25.09 ($48.59) $-26.88 ($35.64)
Cardiovascular disease—Antiplatelet
Clopidogrel 75 mg po daily $88.15 $80.33 ($223.30) $-12.00 ($23.00)
Diabetes—Insulin
NPH (5 vials) $104.71 $-71.90 ($22.81) $-50.40 ($42.24)
Glargline (5 vials) $319.13 $-204.28 ($135.83) $-143.80 ($109.14)
REGULAR (1 vial) $24.33 $-4.35 ($19.38) $-8.84 ($8.15)
Lispro (1 vial) $32.91 $4.55 ($33.73) $4.08 ($18.47)
70/30 pen (5 cartridges) $45.26 $14.20 ($21.81) $12.52 ($13.95)
Diabetes—Thiazolidinedione
Pioglitazone 30 mg po daily 9 30 days $109.33 $-35.33 ($46.99) $-20.00 ($47.41)
Rosiglitazone 4 mg po daily 9 30 days $77.18 $0.86 ($51.65) $14.46 ($60.48)
Chronic obstructive pulmonary disease
Salbutamol and ipratropium (2 MDI each) $77.81 $-37.64 ($19.01) $-34.96 ($19.99)
Salbutamol with ipratropium (1 MDI) $33.98 $15.00 ($22.87) $21.22 ($23.05)
Tiotropium (30 capsules) $79.26 $0.95 ($58.10) $14.65 ($41.06)
a Respondents (n = 31) were asked to estimate the cost of one month’s supply prescribed at hospital discharge
b Actual costs are in Canadian dollars and represent the mean price of the regimen dispensed from three different British Columbia community
pharmacies
c The mean value of pharmacists’ estimates of a medication regimen is compared to the actual cost and the discrepancy reported as an absolute
dollar value (SD = standard deviation)
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Adequate evaluation of patients’ ability to support med-
ication costs may be limited by patient volume and
increasingly rapid or abrupt hospital discharges. To over-
come these barriers, certain organizations have
implemented devoted pharmacist- or nurse-run discharge
services that have improved the efficiency and quality of
prescription decision-making in the discharge planning
process [31–33]. Activities include accommodating more
appropriate therapeutic selections according to patient drug
benefit plans and other financial considerations. Swift and
efficient access to community drug pricing through various
technological mediums would further facilitate responsible
discharge planning. A number of states in the US support
websites with prescription drug cost search engines or
‘‘price finders’’ accessible to both patients and health-care
providers [34, 35]. Hospital medication inventory software
could also be programmed with community drug costs and
linked to inpatient medication profiles. Physician and stu-
dents alike express a desire for more cost information to
consider in medical-decision making processes to reduce
costs to patients and the health care system [20, 21]. Per-
sonalized physician feedback has been demonstrated to alter
prescribing patterns and reduce costs in other studies [20].
While this appears to be the first survey of its kind, there
are a number of limitations which warrant discussion. The
low response rate restricts generalizability to the hospital
pharmacist workforce and resident physicians training
within this health authority and indeed beyond. The patient
and therapeutic scenarios described in the survey were
drawn from general internal medicine cases; respondents
were not asked if they had been involved in the discharge
planning of actual patients receiving these specific thera-
pies and may already be familiar with their cost. Survey
responses would not necessarily reflect accurate discharge
drug cost knowledge of hospital pharmacists who provide
clinical services in different patient care settings or spe-
cialties. The survey also did not identify whether hospital
pharmacist respondents worked in community pharmacy
practice and had dispensed these specific therapies or
otherwise had first-hand knowledge of their price. The
actual costs of therapeutic regimens outlined in the patient
case scenarios were drawn from only three community
pharmacies. Despite the 10% margin for correct estimation,
it is conceivable that actual medication costs may have in
fact varied more widely if data was reported from other
community pharmacy practices and would therefore alter
the proportion of over-and under-estimations. It is expected
that junior resident respondents would be less aware of
prescription costs than their senior resident peers. Finally,
incorrect estimate of drug therapy costs when prompted by
a questionnaire should not imply resident physicians or
pharmacists do not appropriately investigate the discharge
costs for patients at the point of hospital discharge.
Conclusion
Resident physicians and hospital pharmacists were unfa-
miliar with what internal medicine patients must pay for
prescribed discharge therapy once they have returned to the
community. More studies are warranted to further charac-
terize this problem as simple strategies exist to avoid this
ameliorable source for medication non-adherence.
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